BG
AXDX

BlackRock Group’s Accelerate Diagnostics AXDX Stock Holding History

BlackRock Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$330K Buy
1,593
+464
+41% +$110K ﹤0.01% 2494
2016
Q3 		$308K Buy
1,129
+40
+4% +$8.85K ﹤0.01% 2484
2016
Q2 		$157K Sell
1,089
-13
-1% -$1.74K ﹤0.01% 2657
2016
Q1 		$159K Buy
1,102
+404
+58% +$57K ﹤0.01% 2639
2015
Q4 		$149K Sell
698
-18
-3% -$3.29K ﹤0.01% 2585
2015
Q3 		$116K Buy
716
+155
+28% +$33.5K ﹤0.01% 2671
2015
Q2 		$144K Buy
561
+416
+287% +$99.3K ﹤0.01% 2664
2015
Q1 		$33K Hold
145
– – ﹤0.01% 2806
2014
Q4 		$28K Hold
145
– – ﹤0.01% 2817
2014
Q3 		$31K Sell
145
-87
-38% -$16.9K ﹤0.01% 2735
2014
Q2 		$61K Buy
+232
New +$50.6K ﹤0.01% 2675

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

BlackRock Group's AXDX Position: Q4 2016 in Review

BlackRock Group increased its Accelerate Diagnostics (AXDX) stake by 41% in Q4 2016, buying an estimated $110K and bringing the position to 1,593 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

BlackRock Group first reported a position in AXDX in Q2 2014 and has held it in 11 quarters since. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2016.

  • BlackRock Group held 1,593 shares of Accelerate Diagnostics worth $330K as of Q4 2016.
  • BlackRock Group bought 464 Accelerate Diagnostics shares in Q4 2016, an estimated $110K.
  • Accelerate Diagnostics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2494 holding.
  • BlackRock Group first reported a position in Accelerate Diagnostics in Q2 2014 and has held it in 11 quarters since.
  • 109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.